Real-World Safety and Effectiveness of Golimumab in Rheumatic Diseases: Post-Marketing Surveillance in Korea
Crossref DOI link: https://doi.org/10.1007/s40744-021-00352-6
Published Online: 2021-07-29
Published Print: 2021-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kim, Hyeongyeong
Kim, Youngdoe
Lee, YoungJa
Funding for this research was provided by:
Janssen Korea Ltd.
Text and Data Mining valid from 2021-07-29
Version of Record valid from 2021-07-29
Article History
Received: 1 June 2021
Accepted: 15 July 2021
First Online: 29 July 2021